Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results

被引：15

作者：

Raderer, M

Hamilton, G

Kurtaran, A

Valencak, J

Haberl, I

Hoffmann, O

Kornek, GV

Vorbeck, F

Hejna, MHL

Virgolini, I

Scheithauer, W

机构：

[1] Univ Vienna, Dept Internal Med 1, Div Oncol, A-1090 Vienna, Austria

[2] Ludwig Boltzmann Inst Clin Oncol, KH Lainz, Vienna, Austria

[3] Univ Vienna, Dept Nucl Engn, Vienna, Austria

[4] Univ Vienna, Dept Expt Surg, Vienna, Austria

[5] Univ Vienna, Dept Pharmacol & Toxicol, Vienna, Austria

[6] Univ Vienna, Dept Radiol, Vienna, Austria

来源：

BRITISH JOURNAL OF CANCER | 1999年 / 79卷 / 3-4期

关键词：

lanreotide; pancreatic cancer; somatostatin receptors;

D O I：

10.1038/sj.bjc.6690084

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fourteen patients with metastatic pancreatic adenocarcinoma were treated with the long-acting somatostatin (SST) analogue lanreotide. No objective response was obtained, and the median survival was 4 months (range 1.8-7 months). Pancreatic cancer could not be visualized by means of SST-receptor (R) scintigraphy in our patients. In vitro data also demonstrated absence of SSTR2 expression, suggesting pancreatic cancer not to be a potential target for treatment with SST analogues.

引用

页码：535 / 537

页数：3

共 27 条

[1] *ACS, 1991, CANC FACTS FIG 1991
[2] SOMATOSTATIN ANALOG PHASE-I TRIALS IN NEUROENDOCRINE NEOPLASMS
ANTHONY, L
JOHNSON, D
HANDE, K
SHAFF, M
WINN, S
KROZELY, M
OATES, J
[J]. ACTA ONCOLOGICA, 1993, 32 (02) : 217 - 223
[3] BAUER W, 1982, LIFE SCI, V31, P1133, DOI 10.1016/0024-3205(82)90087-X
[4] Buscail L, 1996, CANCER RES, V56, P1823
[5] CANOBBIO L, 1992, CANCER, V69, P648, DOI 10.1002/1097-0142(19920201)69:3<648::AID-CNCR2820690308>3.0.CO
[6] 2-J
[7] INTRAMUSCULAR INJECTIONS OF SLOW-RELEASE LANREOTIDE (BIM-23014) IN ACROMEGALIC PATIENTS PREVIOUSLY TREATED WITH CONTINUOUS SUBCUTANEOUS INFUSION OF OCTREOTIDE (SMS-201-995)
CARON, P
COGNE, M
GUSTHIOTJOUDET, B
WAKIM, S
CATUS, F
BAYARD, F
[J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1995, 132 (03) : 320 - 325
[8] A RANDOMIZED TRIAL OF OCTREOTIDE VS BEST SUPPORTIVE CARE ONLY IN ADVANCED GASTROINTESTINAL CANCER-PATIENTS REFRACTORY TO CHEMOTHERAPY
CASCINU, S
DELFERRO, E
CATALANO, G
[J]. BRITISH JOURNAL OF CANCER, 1995, 71 (01) : 97 - 101
[9] ROLE OF OCTREOTIDE IN THE TREATMENT OF PANCREATIC-CANCER
EBERT, M
FRIESS, H
BEGER, HG
BUCHLER, MW
[J]. DIGESTION, 1994, 55 : 48 - 51
[10] Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer
Glimelius, B
Hoffman, K
Sjoden, PO
Jacobsson, G
Sellstrom, H
Enander, LK
Linne, T
Svensson, C
[J]. ANNALS OF ONCOLOGY, 1996, 7 (06) : 593 - 600

← 1 2 3 →